AI assistant
VOLITIONRX LTD — Director's Dealing 2016
Jan 5, 2016
34395_dirs_2016-01-05_ea3e2dcb-bbc4-4d09-8c7e-994b53e5c7cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2016-01-01
Reporting Person: TERRELL JASON BRADLEY MD (Chief Medical Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 61364 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrant (Right to Buy) | $2.47 | Common Stock (25000) | Direct | ||
| Warrant (Right to Buy) | $2.47 | Common Stock (25000) | Direct | ||
| Warrant (Right to Buy) | $2.47 | Common Stock (50000) | Direct | ||
| Warrant (Right to Buy) | $2.47 | Common Stock (50000) | Direct | ||
| Stock Option (Right to Buy) | $2.5 | 2019-02-18 | Common Stock (12500) | Direct | |
| Stock Option (Right to Buy) | $3 | 2020-02-18 | Common Stock (12500) | Direct |
Footnotes
F1: A total of 25,000 Common Stock Warrants are to vest, if earned, upon the Company signing a second clinical trial agreement in the United States. The Common Stock Warrants shall expire three years from the vesting date.
F2: A total of 25,000 Common Stock Warrants are to vest, if earned, upon the Company signing an agreement with a laboratory/group certified through the CLIA for the use of the Company's proprietary screening kits and devices for the detection of certain diseases in humans in the United States. The Common Stock Warrants shall expire three years from the vesting date.
F3: A total of 50,000 Common Stock Warrants are to vest, if earned, on the date the Company receives approval from the FDA for the sale and distribution in the United States of its first proprietary screening kit or device for the detection of a certain disease. The Common Stock Warrants shall expire three years from the vesting date.
F4: A total of 50,000 Common Stock Warrants are to vest, if earned, on the date the Company receives approval from the FDA for the sale and distribution in the United States of its second proprietary screening kit or device for the detection of a certain disease. The Common Stock Warrants shall expire three years from the vesting date.
F5: A total of 25,000 Stock Options were granted on August 18, 2014 under the Company's 2011 Equity Incentive Plan. The Options vest in two equal installments at 6 months and at 18 months from the date of grant, and expire four years from the vesting date.